Trevena (NASDAQ: TRVN) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Trevena to similar businesses based on the strength of its institutional ownership, analyst recommendations, dividends, earnings, valuation, risk and profitability.

Earnings and Valuation

This table compares Trevena and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Trevena $3.75 million -$102.99 million -1.22
Trevena Competitors $290.27 million $35.99 million 59.83

Trevena’s rivals have higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and recommmendations for Trevena and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevena 0 1 9 0 2.90
Trevena Competitors 917 3337 11836 237 2.70

Trevena presently has a consensus price target of $8.65, indicating a potential upside of 330.35%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.28%. Given Trevena’s stronger consensus rating and higher probable upside, research analysts plainly believe Trevena is more favorable than its rivals.

Risk & Volatility

Trevena has a beta of -0.58, meaning that its share price is 158% less volatile than the S&P 500. Comparatively, Trevena’s rivals have a beta of 2.85, meaning that their average share price is 185% more volatile than the S&P 500.

Insider and Institutional Ownership

56.1% of Trevena shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.6% of Trevena shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


This table compares Trevena and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trevena N/A -150.22% -94.66%
Trevena Competitors -5,189.81% -162.78% -35.24%


Trevena rivals beat Trevena on 7 of the 13 factors compared.

Trevena Company Profile

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Receive News & Stock Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related stocks with our FREE daily email newsletter.